Results 201 to 210 of about 17,182,321 (391)

Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells

Molecular Therapy: Methods & Clinical Development, 2020
T cells modified to co-express cytokine or other factors with chimeric antigen receptor (CAR) can induce substantial and persistent increases in antitumor capacity in vivo.
Yuan Fang, Yajun Zhang, Chuanxin Guo, Chumeng Chen, Haixia Gao, Xiumei Zhou, Tao Liu, Qijun Qian   +7 more
doaj  

Squamous-Celled Carcinoma of the Maxillary Antrum and Ethmoid. Operation—Deep X-Ray Therapy. No Recurrence Five Years Later

, 1931
W. M. Mollison
openalex   +1 more source

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

A Case of Red Cell Aplasia Occurring as a Result of Antituberculous Therapy

, 1964
Stephen B. Goodman, Matthew Block
openalex   +1 more source

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Nature Reviews Clinical Oncology, 2018
S. Neelapu, S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez, F. Locke, K. Komanduri, Yi Lin, N. Jain, N. Daver, J. Westin, A. Gulbis, M. Loghin, J. Groot, S. Adkins, Suzanne E. Davis, K. Rezvani, P. Hwu, E. Shpall   +18 more
semanticscholar   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Cell Cycle Kinetics and Radiation Therapy [PDF]

, 1975
Mortimer L. Mendelsohn
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source